Financial - Conglomerates
Build Your Comparison
Side-by-side financial analysisStock Comparison
ACOG vs AVXL vs SAVA vs JPM vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Banks - Diversified
Biotechnology
ACOG vs AVXL vs SAVA vs JPM vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Financial - Conglomerates | Biotechnology | Biotechnology | Banks - Diversified | Biotechnology |
| Market Cap | $98M | $232M | $64M | $896.00B | $7.70B |
| Revenue (TTM) | $11M | — | $0.00 | $280.33B | $0.00 |
| Net Income (TTM) | $-25M | $-40M | $-106M | $57.05B | $-327M |
| Gross Margin | 86.4% | — | — | 60.0% | — |
| Operating Margin | -250.1% | — | — | 25.9% | — |
| Forward P/E | — | — | — | 14.4x | — |
| Total Debt | $0.00 | $0.00 | $0.00 | $942.38B | $110K |
| Cash & Equiv. | $66M | $103M | $129M | $343.34B | $357M |
ACOG vs AVXL vs SAVA vs JPM vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 24 | Jun 26 | Return |
|---|---|---|---|
| Alpha Cognition Inc… (ACOG) | 100 | 95.2 | -4.8% |
| Anavex Life Science… (AVXL) | 100 | 26.4 | -73.6% |
| Cassava Sciences, I… (SAVA) | 100 | 59.4 | -40.6% |
| JPMorgan Chase & Co. (JPM) | 100 | 128.4 | +28.4% |
| Praxis Precision Me… (PRAX) | 100 | 332.5 | +232.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACOG vs AVXL vs SAVA vs JPM vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ACOG is the #2 pick in this set and the best alternative if bank quality is your priority.
- NIM 2.4% vs JPM's 2.2%
- Better valuation composite
AVXL lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, SAVA doesn't own a clear edge in any measured category.
JPM carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 15 yrs, beta 0.94, yield 1.9%
- Rev growth 3.3%, EPS growth 1.5%
- 465.8% 10Y total return vs ACOG's -11.3%
- Beta 0.94, yield 1.9%, current ratio 0.52x
PRAX ranks third and is worth considering specifically for sleep-well-at-night.
- Lower volatility, beta 1.55, Low D/E 0.0%, current ratio 10.22x
- +491.9% vs AVXL's -69.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 3.3% NII/revenue growth vs SAVA's -5.4% | |
| Value | Better valuation composite | |
| Quality / Margins | 20.4% margin vs ACOG's -232.2% | |
| Stability / Safety | Beta 0.94 vs SAVA's 1.92 | |
| Dividends | 1.9% yield; 15-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +491.9% vs AVXL's -69.6% | |
| Efficiency (ROA) | 1.3% ROA vs SAVA's -75.3%, ROIC 4.5% vs -6.3% |
ACOG vs AVXL vs SAVA vs JPM vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
ACOG vs AVXL vs SAVA vs JPM vs PRAX — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 4 of 6 categories
ACOG leads 0 • AVXL leads 0 • SAVA leads 0 • PRAX leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM and PRAX operate at a comparable scale, with $280.3B and $0 in trailing revenue. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to ACOG's -2.3%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $11M | — | $0 | $280.3B | $0 |
| EBITDAEarnings before interest/tax | -$27M | -$39M | -$110M | $81.4B | -$357M |
| Net IncomeAfter-tax profit | -$25M | -$40M | -$106M | $57.0B | -$327M |
| Free Cash FlowCash after capex | -$30M | -$34M | -$84M | $100.9B | -$283M |
| Gross MarginGross profit ÷ Revenue | +86.4% | — | — | +60.0% | — |
| Operating MarginEBIT ÷ Revenue | -2.5% | — | — | +25.9% | — |
| Net MarginNet income ÷ Revenue | -2.3% | — | — | +20.4% | — |
| FCF MarginFCF ÷ Revenue | -2.8% | — | — | +36.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -146.2% | +54.4% | +62.1% | +16.0% | +2.7% |
Valuation Metrics
Evenly matched — SAVA and JPM and PRAX each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $98M | $232M | $64M | $896.0B | $7.7B |
| Enterprise ValueMkt cap + debt − cash | $32M | $129M | -$65M | $1.50T | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -5.38x | -4.63x | -2.54x | 16.00x | -19.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 14.40x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.90x | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 18.36x | — |
| Price / SalesMarket cap ÷ Revenue | 9.57x | — | — | 3.20x | — |
| Price / BookPrice ÷ Book value/share | 1.78x | 2.25x | 0.42x | 2.47x | 6.83x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 8.88x | — |
Profitability & Efficiency
JPM leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-96 for SAVA. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), JPM scores 5/9 vs SAVA's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -54.1% | -38.8% | -95.8% | +15.9% | -43.0% |
| ROA (TTM)Return on assets | -41.8% | -35.0% | -75.3% | +1.3% | -40.2% |
| ROICReturn on invested capital | -32.4% | — | -6.3% | +4.5% | -65.0% |
| ROCEReturn on capital employed | -38.4% | -47.8% | -99.9% | +8.9% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 | 2 | 5 | 3 |
| Debt / EquityFinancial leverage | — | — | — | 2.60x | 0.00x |
| Net DebtTotal debt minus cash | -$66M | -$103M | -$129M | $599.0B | -$357M |
| Cash & Equiv.Liquid assets | $66M | $103M | $129M | $343.3B | $357M |
| Total DebtShort + long-term debt | $0 | $0 | $0 | $942.4B | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | 0.74x | — |
Total Returns (Dividends Reinvested)
Evenly matched — JPM and PRAX each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $1,191 for AVXL. Over the past 12 months, PRAX leads with a +491.9% total return vs AVXL's -69.6%. The 3-year compound annual growth rate (CAGR) favors PRAX at 164.8% vs AVXL's -33.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -3.1% | -32.1% | -36.8% | -0.5% | -6.9% |
| 1-Year ReturnPast 12 months | -34.4% | -69.6% | -37.7% | +21.8% | +491.9% |
| 3-Year ReturnCumulative with dividends | -11.3% | -71.1% | -62.5% | +138.2% | +1757.4% |
| 5-Year ReturnCumulative with dividends | -11.3% | -88.1% | -87.8% | +118.2% | -14.2% |
| 10-Year ReturnCumulative with dividends | -11.3% | -38.3% | -38.0% | +465.8% | -36.1% |
| CAGR (3Y)Annualised 3-year return | -3.9% | -33.9% | -27.9% | +33.6% | +164.8% |
Risk & Volatility
JPM leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
JPM is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than SAVA's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs AVXL's 17.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.29x | 1.77x | 1.92x | 0.94x | 1.55x |
| 52-Week HighHighest price in past year | $11.54 | $13.99 | $4.98 | $337.25 | $366.52 |
| 52-Week LowLowest price in past year | $4.50 | $2.41 | $1.27 | $262.71 | $37.19 |
| % of 52W HighCurrent price vs 52-week peak | +54.6% | +17.9% | +26.5% | +95.1% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 50.9 | 36.8 | 42.7 | 59.1 | 31.9 |
| Avg Volume (50D)Average daily shares traded | 42K | 1.0M | 134K | 7.0M | 396K |
Analyst Outlook
JPM leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ACOG as "Buy", AVXL as "Buy", SAVA as "Buy", JPM as "Buy", PRAX as "Buy". Consensus price targets imply 340.0% upside for AVXL (target: $11) vs 5.9% for JPM (target: $340). JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $14.00 | $11.00 | — | $339.75 | $607.15 |
| # AnalystsCovering analysts | 1 | 13 | 12 | 61 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +1.9% | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | 15 | — |
| Dividend / ShareAnnual DPS | — | — | — | $5.95 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +3.9% | 0.0% |
JPM leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
ACOG vs AVXL vs SAVA vs JPM vs PRAX: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ACOG or AVXL or SAVA or JPM or PRAX a better buy right now?
For growth investors, JPMorgan Chase & Co.
(JPM) is the stronger pick with 3. 3% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Alpha Cognition Inc. Common Stock (ACOG) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ACOG or AVXL or SAVA or JPM or PRAX?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +118. 2%, compared to -88. 1% for Anavex Life Sciences Corp. (AVXL). Over 10 years, the gap is even starker: JPM returned +465. 8% versus AVXL's -38. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ACOG or AVXL or SAVA or JPM or PRAX?
By beta (market sensitivity over 5 years), JPMorgan Chase & Co.
(JPM) is the lower-risk stock at 0. 94β versus Cassava Sciences, Inc. 's 1. 92β — meaning SAVA is approximately 104% more volatile than JPM relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
04Which is growing faster — ACOG or AVXL or SAVA or JPM or PRAX?
By revenue growth (latest reported year), JPMorgan Chase & Co.
(JPM) is pulling ahead at 3. 3% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ACOG or AVXL or SAVA or JPM or PRAX?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -202. 2% for Alpha Cognition Inc. Common Stock — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -221. 7% for ACOG. At the gross margin level — before operating expenses — ACOG leads at 81. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ACOG or AVXL or SAVA or JPM or PRAX more undervalued right now?
Analyst consensus price targets imply the most upside for AVXL: 340.
0% to $11. 00.
07Which pays a better dividend — ACOG or AVXL or SAVA or JPM or PRAX?
In this comparison, JPM (1.
9% yield) pays a dividend. ACOG, AVXL, SAVA, PRAX do not pay a meaningful dividend and should not be held primarily for income.
08Is ACOG or AVXL or SAVA or JPM or PRAX better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Cassava Sciences, Inc. (SAVA) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, SAVA: -38. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ACOG and AVXL and SAVA and JPM and PRAX?
These companies operate in different sectors (ACOG (Financial Services) and AVXL (Healthcare) and SAVA (Healthcare) and JPM (Financial Services) and PRAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ACOG is a small-cap quality compounder stock; AVXL is a small-cap quality compounder stock; SAVA is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; PRAX is a small-cap quality compounder stock. JPM pays a dividend while ACOG, AVXL, SAVA, PRAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.